Amgen Expands Inflammation Pipeline With Avidia Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
$380 mil. deal for private company gives Amgen Phase I interleukin 6 inhibitor, novel protein development platform.
You may also be interested in...
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
AstraZeneca Commits $100 Million To MedImmune Ventures
The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.
Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”